Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

NCT02690883 on ClinicalTrials.gov · last registry update 2020-03-09

Finished 13 December 2019, after enrolling 92 people. Primary outcome, as filed: the percentage change of 24h-UAER(urinary albumin excretion rates) from baseline at Week 24.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Nanfang Hospital, Southern Medical University
Sponsor type: Other
Enrollment: 92
Started: 2016-04-08
Primary completion: 2019-12-13 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

the percentage change of 24h-UAER(urinary albumin excretion rates) from baseline at Week 24

Conditions studied

Diabetic Nephropathies

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.